How the Mediterranean Diet Affects You: Predicting Responses Based on Your Microbiome
Launched by UNIVERSITY OF BRITISH COLUMBIA · Jan 2, 2025
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how the Mediterranean diet affects people and aims to tailor dietary recommendations based on individual gut bacteria, known as the microbiome. Researchers want to find out if certain types of gut microbes can predict who will benefit most from following this healthy diet compared to a typical Western diet. Participants will receive all their meals and snacks for the study, which will help the team accurately assess how each diet impacts their microbiome.
To join the study, you need to be a healthy adult between the ages of 20 and 50, with a body mass index (BMI) between 20 and 25, and currently not following the Mediterranean diet very closely. You must live in the Okanagan area and have no history of certain health conditions, like diabetes or bowel diseases. If you take antibiotics, have food allergies, or are pregnant or breastfeeding, you won't be eligible. Participants can expect to enjoy meals provided by the study while contributing to important research that could help create personalized diet plans for better health outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy participants, defined as free from cardiovascular disease, diabetes, and hypertension
- • Body Mass Index of 20-25
- • Between the ages 20-50 years
- • Low adherence to the Mediterranean diet (MD serving score \[MDSS\] less than 10 points).
- • Must live in the Okanagan area
- Exclusion Criteria:
- • Individuals with a self-reported history of irritable bowel syndrome, inflammatory bowel disease, Type-2 diabetes, kidney disease, intestinal obstruction, infectious gastroenteritis, colitis or gastritis, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated), malabsorption (such as celiac disease), major surgery of the GI tract, or colorectal cancer
- • Oral antibiotics within three months of the intervention start date
- • Individuals with any known food allergies, reported dietary intolerances of any kind, and those with eating disorders
- • Pregnant or breastfeeding
- • Participants with a high MDSS (\> 10 points)
- • Individuals who are intermittent fasting or refuse to follow the study protocol
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kelowna, British Columbia, Canada
Patients applied
Trial Officials
Natasha Haskey, RD PHD
Principal Investigator
University of British Columbia
Maitreyi Raman, MSc MD FRCPC
Principal Investigator
University of Calgary
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported